Definitive radiotherapy for early stage glottic cancer by 6 MV photons

Tong, Chi-Chung; Au, Kwok‐Hung; Ngan, Roger K.C.; Cheung, Foon-Yiu; Chow, Sin‐Ming; Fu, Yiu-Tung; Au, Joseph Siu-Kie; Law, Stephen C.K.

doi:10.1186/1758-3284-4-23

Cited by 18 publications

(14 citation statements)

References 33 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients treated with radiation therapy (RT) for tumor (T)1 glottic squamous cell carcinoma have excellent disease control rates, with a general local control probability >90% for T1a disease, and ranging from 64% to 93% for T1b . The conventional radiation therapy (ConRT) technique uses opposed lateral radiation fields that give full or greater dose to the adjacent carotid arteries .…”

Section: Introductionmentioning

confidence: 99%

Outcomes of carotid‐sparing IMRT for T1 glottic cancer: Comparison with conventional radiation

Mohamed

Smith

et al. 2019

The Laryngoscope

View full text Add to dashboard Cite

Objectives: We aim to report oncologic outcomes after conventional radiotherapy (ConRT) using opposed lateral beams and intensity-modulated radiation therapy (IMRT) for tumor (T)1 nodal (N)0 T1 N0 glottic squamous cell carcinoma.Study Design: Retrospective case-control study. Methods: We retrospectively reviewed demographic, disease, and treatment characteristics for patients treated at our institution during 2000 to 2013.Results: One hundred fifty-three patients (71%) were treated using ConRT and 62 (29%) using IMRT. The median follow-up for all patients was 68 months. There was no statistically significant difference in 5-year local control between patients with T1a versus T1b disease (94% vs. 89%, respectively, P = 0.5). Three-year locoregional control for patients treated with ConRT was 94% compared to 97% with IMRT (P = 0.4). Three-year overall survival (OS) for patients treated with ConRT was 92.5% compared with 100% with IMRT (P = 0.1). Twelve of 14 patients with local recurrence underwent salvage surgery with 5-year ultimate locoregional control of 98.5% and 97.1% in the ConRT and IMRT cohorts, respectively (P = 0.7). Multivariate analysis showed age < 60 years (P < 0.0001) and pretreatment Eastern Cooperative Oncology Group performance status <2 (P = 0.0022) to be independent correlates of improved OS. Postradiation cerebrovascular events were in four patients in the ConRT cohort (3%), whereas no patients in the IMRT cohort suffered any events.Conclusion: Because the oncologic outcomes for patients treated with IMRT were excellent and IMRT allows for carotid sparing, we have transitioned to IMRT as our standard for most patients with T1 glottic cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Outcomes of carotid‐sparing IMRT for T1 glottic cancer: Comparison with conventional radiation

Mohamed

Smith

et al. 2019

The Laryngoscope

View full text Add to dashboard Cite

show abstract

“…The purpose of treating T1/T2 laryngeal cancer is to cure the disease with larynx function preservation, most specifically the maintenance of voice function and quality . Many past researches have regarded RT as the mainstay of treatment for such patients . A study from Australia highlighted the importance by concluding that RT for early‐stage laryngeal cancer results in both subjective and objective improvements in voice quality .…”

Section: Discussionmentioning

confidence: 99%

“…1,23 Many past researches have regarded RT as the mainstay of treatment for such patients. 24 A study from Australia highlighted the importance by concluding that RT for early-stage laryngeal cancer results in both subjective and objective improvements in voice quality. 25 Technological advancements continue to provide radiation oncologists with new treatment approaches that result in dose reduction to uninvolved non-target tissues.…”

Section: Discussionmentioning

confidence: 99%

Dosimetric and radiobiologic comparison of 3D conformal, IMRT, VMAT and proton therapy for the treatment of early‐stage glottic cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…A 6 MV photon line was selected, and electron beam irradiation with appropriate energy was applied on the posterior region of neck. Its radiation dose was Dt60-70 Gy/6-7 weeks (2.0 Gy/d, 5 times a week),3 and the spinal cord dose was less than 40 Gy. The patients who could receive surgery after radiotherapy for N2 or above lymph node metastasis were subjected to cervical lymph node dissection.…”

Section: Methodsmentioning

confidence: 99%

Therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer

Tao

Yin

et al. 2016

Pak J Med Sci

View full text Add to dashboard Cite

Objective:To explore the therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer (LALC).Methods:Fifty LALC patients who were treated in our hospital between January 2010 and January 2012 were selected and randomly divided into an observation group and a control group (n=25). The two groups were given conventional radiotherapy in the same manner, before which two cycles of chemotherapy were performed. The observation group intravenously infused with 500 mg/m2 pemetrexed on d1 and 25 mg/m2 cisplatin on d1-3, with 28 days as a cycle. The control group was intravenously infused with 25 mg/m2 cisplatin on d1-3 and 400 mg/m2 fluorouracil, with 28 days as a cycle. The short-term effects and adverse reactions of both groups were observed after treatment, and their survival was observed by follow-up for five years.Results:The response rate was 84% (21/25) in the observation group and 64% (16/25) in the control group, between which the difference was statistically significant (P<0.05). The differences in the incidence rates of short-term adverse reactions such as grade III-IV gastrointestinal reactions and bone marrow suppression were not statistically significant between PC regimen (pemetrexed combined with cisplatin) and PF regimen (cisplatin combined with fluorouracil) (P>0.05). The incidence of long-term adverse reactions such as grade III-IV laryngeal edemas, laryngeal cartilage inflammation and laryngeal cartilage necrosis showed no significant differences between the two groups (P>0.05). The median survival was 3.3 years after PC chemotherapy and 2.8 years after PF chemotherapy, between which the difference was not statistically significant (P>0.05). The levels of serum tumor markers significantly decreased after PC and PF treatments compared with those before (P<0.05).Conclusion:Combining PC chemotherapy with radiotherapy has satisfactory short-term therapeutic effects on LALC, and the resulting adverse effects can be tolerated. Therefore, this strategy is worthy of promotion and application in clinical practice.

show abstract

Definitive radiotherapy for early stage glottic cancer by 6 MV photons

Cited by 18 publications

References 33 publications

Outcomes of carotid‐sparing IMRT for T1 glottic cancer: Comparison with conventional radiation

Outcomes of carotid‐sparing IMRT for T1 glottic cancer: Comparison with conventional radiation

Dosimetric and radiobiologic comparison of 3D conformal, IMRT, VMAT and proton therapy for the treatment of early‐stage glottic cancer

Therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer

Contact Info

Product

Resources

About